Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPierre SesquesRHRoch HouotYTYassine Al Tabaa

Discussion

Loading...

Member takes

Overview

Phase II trial shows Glofitamab significantly improves overall survival in DLBCL patients after CAR T-cell failure, suggesting a superior treatment option.

Key Points

  • The study aims to evaluate the efficacy of glofitamab in patients with diffuse large B-cell lymphoma after CAR T-cell therapy failure.
  • Conducted a phase II trial (BiCAR study) involving patients with biopsy-confirmed CD20+ DLBCL and no metabolic response after CAR T-cell therapy.
  • Administered obinutuzumab before starting glofitamab with a rapid step-up dosing schedule.
  • Used stabilized inverse probability of treatment weighting for comparative analysis against the synthetic control arm.
  • Median overall survival (mOS) was 17.3 months for glofitamab-treated patients compared to 7.6 months in the synthetic control.
  • Overall best response rate was 76.1%, with 45.7% achieving a complete response.
  • Median progression-free survival was 3.8 months, indicating treatment activity.

Cite This Study

Sesques et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5abhttps://doi.org/10.1182/blood-2025-1958
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm2026
  2. 2Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  3. 3Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort2026